CD47 and neoplasm: Our in vitro studies demonstrate that GenSci059 effectively blocks the interaction between CD47 and its inhibitory receptor SIRPα, leading to a dose-dependent promotion of tumor cell phagocytosis by both mouse and human macrophages.